




Instance: composition-en-a52e8d08d74bb225bb0d5cb64a7b9638
InstanceOf: CompositionUvEpi
Title: "Composition for renagel Package Leaflet"
Description:  "Composition for renagel Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp38d06c606097a82b9907752569c86e20)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - renagel"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Renagel is and what it is used for </li>
<li>What you need to know before you take Renagel </li>
<li>How to take Renagel </li>
<li>Possible side effects </li>
<li>How to store Renagel </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What renagel is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What renagel is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Renagel contains sevelamer as the active ingredient. It binds phosphate from food in the digestive tract 
and so reduces serum phosphate levels in the blood. </p>
<p>Renagel is used to control the levels of phosphate in the blood of adult kidney failure patients on 
haemodialysis or peritoneal dialysis treatment.  </p>
<p>Adult patients whose kidneys have failed and who are undergoing haemodialysis or peritoneal dialysis 
are not able to control the level of serum phosphate in their blood. The amount of phosphate then rises 
(your doctor will call this hyperphosphataemia). Increased levels of serum phosphorus can lead to hard 
deposits in your body called calcification. These deposits can stiffen your blood vessels and make it 
harder for blood to be pumped around the body. Increased serum phosphorus can also lead to itchy 
skin, red eyes, bone pain and fractures. </p>
<p>Renagel may be used with other medicines which include calcium or vitamin D supplements to control 
the development of renal bone disease. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take renagel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take renagel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Renagel: 
* if you have low levels of phosphate in your blood (your doctor will check this for you). 
* if you have bowel obstruction.<br />
* if you are allergic to sevelamer or to any of the other ingredients of this medicine (listed in 
section 6). </p>
<p>Warnings and precautions 
Talk to your doctor before taking Renagel if any of the following applies to you: 
  if you are not on dialysis 
  if you have swallowing problems 
  if you have problems with motility (movement) in your stomach and bowel 
  if you have symptoms of delayed emptying of stomach contents such as feeling of fullness, 
nausea and/or vomiting<br />
  if you have prolonged diarrhoea or pain in the abdomen (symptoms of active inflammatory 
bowel disease) 
  if you have undergone major surgery on your stomach or bowel </p>
<p>Talk to your doctor while taking Renagel: 
  if you experience severe abdominal pain, stomach or intestine disorders, or blood in the stool 
(gastrointestinal bleeding). These symptoms can be due to serious inflammatory bowel disease 
caused by sevelamer crystals deposit in your bowel. Contact your doctor who will decide on 
continuing the treatment or not. </p>
<p>Additional treatments: 
Due to either your kidney condition or your dialysis treatment you may: 
  develop a low or high level of calcium in your blood. Since Renagel does not contain calcium 
your doctor might prescribe additional calcium tablets. 
  have a low amount of vitamin D in your blood. Therefore, your doctor may monitor the levels 
of vitamin D in your blood and prescribe additional vitamin D as necessary. If you do not take 
multivitamin supplements you may also develop low levels of vitamins A, E, K and folic acid in 
your blood and therefore your doctor may monitor these levels and prescribe supplemental 
vitamins as necessary. </p>
<p>Changing treatment: 
When you switch from another phosphate binder to Renagel, your doctor might consider monitoring 
the levels of bicarbonate in your blood more closely because Renagel may decrease the levels of 
bicarbonate. </p>
<p>Special note for patients on peritoneal dialysis 
You may develop peritonitis (infection of your abdominal fluid) associated with your peritoneal 
dialysis. This risk can be reduced by careful adherence to sterile techniques during bag changes. You 
should tell your doctor immediately if you experience any new signs or symptoms of abdominal 
distress, abdominal swelling, abdominal pain, abdominal tenderness, or abdominal rigidity, 
constipation, fever, chills, nausea or vomiting. 
You should expect to be monitored more carefully for problems with low levels of vitamins A, D, E, 
K and folic acid. </p>
<p>Children and adolescents 
The safety and efficacy in children (below the age of 18 years) has not been studied. Therefore 
Renagel is not recommended for use in this population. </p>
<p>Other medicines and Renagel 
Tell your doctor if you are taking, have recently taken or might take any other medicines. </p>
<p>Renagel should not be taken at the same time as ciprofloxacin (an antibiotic). </p>
<p>If you are taking medicines for heart rhythm problems or for epilepsy, you should consult your 
doctor when taking Renagel. </p>
<p>The effects of medicines such as ciclosporin, mycophenolate mofetil and tacrolimus 
(medicines used in transplant patients) may be reduced by Renagel. Your doctor will advise 
you if you are taking these medicines. </p>
<p>In certain people taking levothyroxine (a thyroid hormone) and Renagel, increased levels of 
thyroid stimulating hormone (TSH, a substance in your blood which helps control your body s 
chemical functions) may very rarely be observed. Therefore your doctor may monitor the 
levels of TSH in your blood more closely. </p>
<ul>
<li>If you are taking medicine such as omeprazole, pantoprazole, or lansoprazole to treat heartburn, 
gastroesophageal reflux disease (GERD), or gastric ulcers, you should consult your doctor when 
taking Renagel. </li>
</ul>
<p>Your doctor will check for interactions between Renagel and other medicines on a regular basis. </p>
<p>In some cases where Renagel should be taken at the same time as another medicine, your doctor may 
advise you to take this medicine 1 hour before or 3 hours after Renagel intake, or he/she may consider 
monitoring the blood levels of that medicine. </p>
<p>Pregnancy and  breast-feeding 
The safety of Renagel has not been established in pregnant or breast-feeding women. Renagel should 
only be given to pregnant or breast-feeding women if clearly needed. </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine.  </p>
<p>Driving and using machines 
Renagel is unlikely to affect your ability to drive or to use machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take renagel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take renagel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not 
sure. He will base the dose on your serum phosphate level. The recommended starting dose of Renagel 
for adults and the elderly (&gt;65 years) is two to four tablets with each meal 3 times a day. </p>
<p>Initially your doctor will check the levels of phosphate in your blood every 2-3 weeks and  may adjust 
the dose of Renagel when necessary (between 1 and 10 tablets of 400 mg per meal) to reach an 
adequate phosphate level. </p>
<p>The tablets must be swallowed whole. Do not crush, chew or break into pieces prior to swallowing. </p>
<p>Patients taking Renagel should adhere to their prescribed diet and liquid intake.  </p>
<p>If you take more Renagel than you should 
In the event of a possible overdose you should contact your doctor immediately. </p>
<p>If you forget to take Renagel 
If you have missed one dose, this dose should be omitted and the next dose should be taken at the 
usual time with a meal. Do not take a double dose to make up for a forgotten dose. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine  can cause side effects, although not everybody gets them. </p>
<p>Since constipation may be a preceding symptom in very rare cases of blockages in your intestine, it is 
important to inform your doctor or pharmacist of this symptom before or during the use of Renagel. </p>
<p>The following side effects have been reported in patients taking Renagel:<br />
Very common (may affect more than 1 in 10 people): 
nausea, vomiting. 
Common (may affect up to 1 in 10 people):<br />
diarrhoea, indigestion, abdominal pain, constipation, flatulence. 
Uncommon (may affect up to 1 in 100 people):<br />
increased acidity of the blood.<br />
Very rare (may affect up to 1 in 10000 people): 
hypersensitivity. 
Not known (frequency cannot be estimated from the available data): 
cases of itching, rash, abdominal pain, slow intestine motility (movement), inflammation of abnormal 
small pouches (called diverticula) in the large intestine, blockages in the intestine (signs include: 
severe bloating; abdominal pain, swelling or cramps; severe constipation),  rupture in the intestine wall 
(signs include: severe stomach pain, chills, fever, nausea, vomiting, or a tender abdomen), serious 
inflammation of the large bowel (symptoms include: severe abdominal pain, stomach or intestine 
disorders, or blood in the stool [gastrointestinal bleeding]) and crystal deposit in the intestine have 
been reported. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store renagel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store renagel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date stated on the carton and bottle after  EXP . The expiry 
date refers to the last day of that month. </p>
<p>Do not store this medicine above 25  C. Keep the bottle tightly closed in order to protect from 
moisture.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Renagel contains </p>
<ul>
<li>The active substance is sevelamer hydrochloride. Each tablet contains 400 mg sevelamer 
hydrochloride. </li>
<li>The other ingredients are silica colloidal anhydrous and stearic acid, hypromellose (E464), 
diacetylated monoglycerides, iron oxide black (E172) and propylene glycol. </li>
</ul>
<p>What Renagel looks like and contents of the pack </p>
<p>Renagel tablets are film coated, off white, oval tablets with Renagel 400 imprinted on one side. The 
tablets are packed in high density polyethylene bottles with a child resistant polypropylene closure and 
an induction seal. </p>
<p>Pack sizes are: 
1 bottle of 360 tablets 
multipacks containing 720 tablets  (2 bottles of 360 tablets) 
multipacks containing 1080 tablets  (3 bottles of 360 tablets) </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Marketing Authorisation Holder: 
Sanofi B.V. 
Paasheuvelweg 1105 BP Amsterdam 
The Netherlands </p>
<p>Manufacturer:<br />
Genzyme Ireland Limited 
IDA Industrial Park 
Old Kilmeaden Road 
Waterford 
Ireland </p>
<p>Sanofi Winthrop Industrie 
1 rue de la Vierge 
Ambares et Lagrave 
33565 Carbon Blanc cedex 
France </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien/ 
Luxembourg/Luxemburg 
Sanofi Belgium 
T l/Tel: + 32 2 710 54 Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91 <br />
Swixx Biopharma EOOD 
 .: +359 (0)2 4942 Magyarorsz g 
SANOFI-AVENTIS Zrt 
Tel: +36 1 505 0 esk  republika 
sanofi-aventis, s.r.o. 
Tel: +420 233 086 Malta 
Sanofi S.r.l. 
Tel: +39 02 39394Danmark 
Sanofi A/S<br />
Tlf: +45 45 16 70 Nederland 
Sanofi B.V. 
Tel: +31 20 245 4Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel: 0800 52 52 Tel. aus dem Ausland: +49 69 305 21 Norge 
sanofi-aventis Norge AS 
Tlf: + 47 67 10 71 Eesti 
Swixx Biopharma O <br />
Tel: +372 640 10  sterreich 
sanofi-aventis GmbH 
Tel: + 43 1 80 185 - 0 </p>
<p>Sanofi-Aventis   AEBE 
 : +30 210 900 1Polska 
sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00 Espa a 
sanofi-aventis, S.A. 
Tel: +34 93 485 94 Portugal 
Sanofi   Produtos Farmac uticos, Lda. 
Tel: +351 21 35 89 France 
Rom nia 
Sanofi Winthrop Industrie 
T l : 0 800 222 Appel depuis l tranger : +33 1 57 63 23 Sanofi Romania SRL 
Tel: +40 (0) 21 317 31 Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078 Slovenija 
Swixx Biopharma d.o.o.<br />
Tel: +386 1 235 51 Ireland 
sanofi-aventis Ireland Ltd T/A SANOFI 
Tel:  +353 (0) 1 4035 Slovensk  republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 208 33  sland 
Vistor hf. 
S mi: +354 535 7Suomi/Finland 
Sanofi Oy 
Puh/Tel: + 358 201 200 Italia 
Sanofi S.r.l. 
Tel: 800 536 Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50 <br />
C.A. Papaellinas Ltd. 
 : +357 22 741United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2Latvija 
Swixx Biopharma SIA<br />
Tel: +371 6 616 47 This leaflet was last revised in   </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-a52e8d08d74bb225bb0d5cb64a7b9638
InstanceOf: CompositionUvEpi
Title: "Composition for renagel Package Leaflet"
Description:  "Composition for renagel Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp38d06c606097a82b9907752569c86e20)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - renagel"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Renagel 
3. Sådan skal du tage Renagel 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger. </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What renagel is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What renagel is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Renagel indeholder sevelamer som er det aktive stof. Det binder fosfat fra levnedsmidler i 
fordøjelseskanalen og reducerer derved fosfatkoncentrationen i blodet. </p>
<p>Renagel anvendes til at kontrollere fosfatkoncentrationen i blodet hos voksne patienter med nyresvigt, 
som er i hæmodialyse eller peritonealdialyse.  </p>
<p>Voksne patienter med nyresvigt, og som er i hæmodialyse eller peritonealdialyse, kan ikke opretholde 
normalt serumfosfatniveau i blodet. Mængden af fosfat stiger således (dette kaldes hyperfosfatæmi). 
Et øget indhold af serumfosfat kan føre til hårde aflejringer i din krop. Dette kaldes forkalkning. 
Aflejringerne kan gøre dine blodkar stive og gøre det mere besværligt for blodet at blive pumpet rundt 
i kroppen. Øget serumfosfat kan også medføre hudkløe, røde øjne og smerter i eller brud på knogler. </p>
<p>Renagel kan anvendes sammen med andre lægemidler, herunder calciumtilskud eller D-
vitamintilskud, for at behandle udviklingen af renal knoglesygdom. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take renagel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take renagel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Renagel: </p>
<ul>
<li>
<p>Hvis du har lavt fosfatindhold i blodet (din læge vil måle dette for dig) </p>
</li>
<li>
<p>Hvis du har forstoppelse i tarmen </p>
</li>
<li>
<p>Hvis du er allergisk over for sevelamer eller et af de øvrige indholdsstoffer (angivet i punkt 6). </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Hvis et eller flere af følgende punkter gælder for dig, skal du kontakte lægen, før du begynder at tage 
Renagel. </p>
<ul>
<li>
<p>Hvis du ikke er i dialyse </p>
</li>
<li>
<p>Hvis du har synkebesvær </p>
</li>
<li>
<p>Hvis du har problemer med bevægelserne (motiliteten) i mave-/tarm-kanalen </p>
</li>
<li>
<p>Hvis du har symptomer på forsinket tømning af maveindholdet, såsom følelse af mæthed, 
kvalme og / eller opkastning </p>
</li>
<li>
<p>Hvis du har længerevarende diarré eller smerter i maven (symptomer på inflammatorisk 
tarmsygdom)  </p>
</li>
<li>
<p>Hvis du har gennemgået en større operation i mave-/tarmkanalen </p>
</li>
</ul>
<p>Tal med din læge, mens du tager Renegal: 
• Hvis du oplever svære abdominale smerter, mave-eller tarmsygdomme, eller blod i afføringen 
(gastroinstetinal blødning). Disse symptomer kan skyldes alvorlig inflammatorisk 
tarmsygdom forårsagt af sevelamerkrystaller aflejret i tarmen. Kontakt din læge,  der vil 
beslutte om behandlingen skal fortsætte eller ej.  </p>
<p>Yderligere behandling: 
På grund af enten din nyresygdom eller dialysebehandlingen kan du:  </p>
<ul>
<li>
<p>udvikle et nedsat eller forhøjet calciumniveau i blodet. Da Renagel ikke indeholder calcium, 
kan lægen ordinere supplerende calciumtabletter. </p>
</li>
<li>
<p>have et lavt indhold af D-vitamin i blodet. Din læge kan derfor finde det hensigtsmæssigt at 
følge D-vitaminkoncentrationen i blodet og om nødvendigt give ekstra D-vitamintilskud. Hvis 
du ikke tager multivitamintilskud, kan du også udvikle lave niveauer af vitamin A, E, K og 
folinsyre i blodet, og lægen kan derfor holde øje med disse niveauer og ordinere 
vitamintilskud om nødvendigt. </p>
</li>
</ul>
<p>Skift af behandling: 
Ved skift fra en anden fosfatbinder til Renagel vil lægen måske overveje at overvåge 
bikarbonatniveauet i dit blod nøjere, fordi Renagel kan reducere bikarbonatniveauerne. </p>
<p>Særlige bemærkninger for patienter i peritonealdialyse 
Du kan udvikle peritonitis (bughindebetændelse) i forbindelse med peritonealdialysen. Denne risiko 
kan reduceres ved omhyggelig overholdelse af sterile teknikker under poseskift. Du skal omgående 
fortælle lægen det, hvis du oplever nye tegn eller symptomer på fordøjelsesproblemer, opsvulmet 
mave, mavesmerter, maveømhed eller stivhed i maven, forstoppelse, feber, kuldegysninger, kvalme og 
opkastning. 
Desuden skal du forvente at blive overvåget nøjere for problemer med lave niveauer af vitamin A, D, 
E, K og folinsyre. </p>
<p>Børn og unge 
Sikkerheden og virkningen af Renagel er ikke fastlagt for børn (under 18 år). Derfor anbefales 
Renagel ikke til børn (under 18 år). </p>
<p>Brug af anden medicin sammen med Renagel 
Fortæl altid lægen, hvis du tager eller for nylig har taget eller måske skal tage anden medicin. </p>
<ul>
<li>
<p>Renagel må ikke tages samtidig med ciprofloxacin (et antibiotikum). </p>
</li>
<li>
<p>Hvis du tager medicin for problemer med hjerterytmen eller for epilepsi, skal du diskutere det 
med lægen, når du tager Renagel.  </p>
</li>
<li>
<p>Effekten af medicin såsom ciclosporin, mycophenolatmofetil og tacrolimus (medicin, som 
anvendes til transplantationspatienter) kan reduceres af Renagel. Lægen vil rådgive dig, hvis du 
tager disse lægemidler. </p>
</li>
<li>
<p>Hos visse personer, der tager levothyroxin (et thyroideahormon) og Renagel kan, forhøjede 
niveauer af thyroideastimulerende hormon (TSH, et stof i blodet, som medvirker til at 
kontrollere kroppens kemiske funktion) forekomme i yderst sjældne tilfælde. Derfor vil lægen 
muligvis holde nærmere øje med TSH-niveauerne i dit blod. </p>
</li>
<li>
<p>Hvis du tager medicin til behandling af halsbrand, gastroøsofageal reflukssygdom (GØRS) eller 
mavesår, såsom omeprazol, pantoprazol, eller lansoprazol, skal du konsultere din læge, når du 
tager Renagel. </p>
</li>
</ul>
<p>Lægen vil jævnligt kontrollere for interaktioner mellem Renagel og anden medicin. </p>
<p>I visse tilfælde, hvor Renagel skal tages på samme tid som en anden medicin, kan din læge råde dig til 
at tage medicinen 1 time før eller 3 timer efter indtagelsen af Renagel, eller han / hun kan overveje at 
kontrollere blodets indhold af medicinen. </p>
<p>Graviditet og amning 
Sikkerheden ved anvendelse af Renagel til gravide og ammende kvinder er ikke blevet fastlagt. 
Renagel må kun gives til gravide eller ammende kvinder, hvis der er et klart behov.  </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
Det er usandsynligt, at Renagel påvirker din evne til at køre bil eller betjene maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take renagel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take renagel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen. Lægen vil 
fastsætte doseringen ud fra indholdet af serumfosfat i dit blod. Den anbefalede startdosis for Renagel 
er for voksne og ældre personer (&gt; 65 år)  to til fire tabletter sammen med hvert måltid 3 gange daglig.  </p>
<p>I starten vil lægen måle fosfatindholdet i dit blod hver 2.-3. uge, og ændrer om nødvendigt doseringen 
af Renagel (mellem 1 og 10 tabletter på 400 mg pr. måltid) for at opnå den ønskede 
fosfatkoncentration i blodet. </p>
<p>Tabletterne skal sluges hele. Må ikke knuses, tygges eller brækkes i stykker inden indtagelse.  </p>
<p>Patienter, der tager Renagel, skal holde sig til deres foreskrevne diæt og væskeindtagelse. </p>
<p>Hvis du har taget for mange Renagel 
I tilfælde af en eventuel overdosis, skal du straks søge læge. </p>
<p>Hvis du har glemt at tage Renagel 
Hvis du er kommet til at springe en dosis over, udelades denne dosis, og den næste dosis tages på det 
normale tidspunkt i forbindelse med et måltid. Du må ikke tage en dobbeltdosis som erstatning for den 
glemte dosis. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Forstoppelse kan i meget sjældne tilfælde være et tidligt symptom på tilstopning af tarmene. Det er 
vigtigt at informere lægen eller apoteket om dette symptom før eller under anvendelse af Renagel. </p>
<p>Følgende bivirkninger er rapporteret hos patienter, der tager Renagel:<br />
Meget almindelig (kan påvirke flere end 1 ud af 10 personer):<br />
kvalme, opkastning 
Almindelig (kan påvirke op til 1 ud af 10 personer):<br />
diaré, fordøjelsesproblemer, mavesmerter, forstoppelse, luft fra tarmen. 
Ikke almindelig (kan påvirke op til 1 ud af 100 personer): 
for meget syre i blodet.<br />
Meget sjælden (kan påvirke op til 1 ud af 10.000 personer): 
overfølsomhed. 
Ikke kendt (kan ikke vurderes ud fra tilgængelige data): 
kløe, udslæt, mavesmerter, langsom bevægelse i tarmene (tarmmotilitet), betændelse i udposninger 
(kaldet divertikler) af tyktarmen, blokering af tarmen (symptomerne kan være: svær oppustethed, 
mavesmerter, hævelse eller kramper, svær forstoppelse), revne i tarmvæggen (symptomerne kan være: 
svære mavesmerter, kulderystelser, feber, kvalme, opkastning eller ømhed i maven), alvorlig 
tyktarmsbetændelse (symptomer kan være: svære abdominale smerter, mave-eller tarmsygdomme, 
eller blod i afføringen [gastroinstetinal blødning]) og krystalaflejringer i tarmene er blevet rapporteret. </p>
<p>Indberetning af formodede bivirkninger 
Når lægemidlet er godkendt, er indberetning af formodede bivirkninger vigtig. Det muliggør løbende 
overvågning af benefit/risk-forholdet for lægemidlet. Læger og sundhedspersonale anmodes om at 
indberette alle formodede bivirkninger til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store renagel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store renagel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, som står på pakningen efter Exp. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 25 °C. Hold flasken tæt tillukket for at beskytte indholdet 
mod fugt.  </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Renagel indeholder:</p>
<ul>
<li>Aktivt stof: sevelamerhydrochlorid. Hver tablet indeholder 400 mg sevelamerhydrochlorid. </li>
<li>Øvrige indholdsstoffer: kolloid vandfri silica og stearinsyre, hypromellose (E464), diacetylerede 
monoglycerider, sort jernoxid (E172) og propylenglykol.  </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Renagel er filmovertrukne, offwhite, ovale tabletter, som har påtrykt Renagel 400 på én side. 
Tabletterne er pakket i meget tætte polythylenflasker med børnesikret polypropylenlåg samt et 
induktionssegl.  </p>
<p>Pakningsstørrelser:<br />
1 flaske med 360 tabletter 
multipakninger med 720 tabletter (2 flasker med 360 tabletter) 
multipakninger med 1080 tabletter (3 flasker med 360 tabletter) </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller:  </p>
<p>Indehaver af markedsføringstilladelsen: 
Sanofi B.V.<br />
Paasheuvelweg 1105 BP Amsterdam 
Holland </p>
<p>Fremstiller: 
Genzyme Ireland Limited. 
IDA Industrial Park 
Old Kilmeaden Road 
Waterford 
Irland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien/ 
Luxembourg/Luxemburg 
Sanofi Belgium 
Tél/Tel: + 32 2 710 54<br />
Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91<br />
България 
Swixx Biopharma EOOD 
Тел.: +359 (0)2 4942<br />
Magyarország 
SANOFI-AVENTIS Zrt 
Tel: +36 1 505 0Česká republika 
sanofi-aventis, s.r.o. 
Tel: +420 233 086<br />
Malta 
Sanofi S.r.l. 
Tel: +39 02 39394Danmark 
Sanofi A/S 
Tlf: +45 45 16 70<br />
Nederland 
Sanofi B.V.<br />
Tel: +31 20 245 4Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel: 0800 52 52 Tel. aus dem Ausland: +49 69 305 21<br />
Norge 
sanofi-aventis Norge AS 
Tlf: + 47 67 10 71<br />
Eesti 
Swixx Biopharma OÜ<br />
Tel: +372 640 10 <br />
Österreich 
sanofi-aventis GmbH 
Tel: + 43 1 80 185 - 0 
Ελλάδα 
Sanofi-Aventis Μονοπρόσωπη AEBE<br />
Τηλ: +30 210 900 1Polska 
sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00<br />
España 
sanofi-aventis, S.A. 
Tel: +34 93 485 94 <br />
Portugal 
Sanofi - Produtos Farmacêuticos, Lda. 
Tel: +351 21 35 89<br />
France 
Sanofi Winthrop Industrie<br />
Tél : 0 800 222 Appel depuis l’étranger : +33 1 57 63 23<br />
România 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31 36<br />
Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078<br />
Slovenija 
Swixx Biopharma d.o.o.<br />
Tel: +386 1 235 51<br />
Ireland 
sanofi-aventis Ireland Ltd T/A SANOFI 
Slovenská republika 
Swixx Biopharma s.r.o. 
Tel: +353 (0) 1 4035 600  </p>
<p>Tel: +421 2 208 33 <br />
Ísland 
Vistor hf. 
Sími: +354 535 7 
Suomi/Finland 
Sanofi Oy 
Puh/Tel: + 358 201 200<br />
Italia 
Sanofi S.r.l. 
Tel: 800 536<br />
Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50 Κύπρος 
C.A. Papaellinas Ltd. 
Τηλ: +357 22 741 
United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2 
Latvija 
Swixx Biopharma SIA<br />
Tel: +371 6 616 47  </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om Renagel på Det Europæiske Lægemiddelagenturs hjemmeside 
http://www.ema.europa.eu/. </p>
<p>Indlægsseddel: Information til brugeren </p>
<p>Renagel 800 mg filmovertrukne tabletter 
sevelamerhydrochlorid </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. </p>
<ul>
<li>
<p>Gem indlægssedlen. Du kan få brug for at læse den igen. </p>
</li>
<li>
<p>Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. </p>
</li>
<li>
<p>Lægen har ordineret dette lægemiddel til dig personligt. Lad derfor være med at give det til 
andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har. </p>
</li>
<li>
<p>Kontakt lægen, hvis en bivirkning bliver værre, eller du får bivirkninger, som ikke er nævnt 
her. Se punkt 4. Oversigt over indlægssedlen: </p>
</li>
</ul>         </div>"""      





                    
Instance: bundlepackageleaflet-en-a52e8d08d74bb225bb0d5cb64a7b9638
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for renagel Package Leaflet for language en"
Description: "ePI document Bundle for renagel Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-a52e8d08d74bb225bb0d5cb64a7b9638"
* entry[0].resource = composition-en-a52e8d08d74bb225bb0d5cb64a7b9638

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa52e8d08d74bb225bb0d5cb64a7b9638"
* entry[=].resource = mpa52e8d08d74bb225bb0d5cb64a7b9638
                            
                    
Instance: bundlepackageleaflet-da-a52e8d08d74bb225bb0d5cb64a7b9638
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for renagel Package Leaflet for language da"
Description: "ePI document Bundle for renagel Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-a52e8d08d74bb225bb0d5cb64a7b9638"
* entry[0].resource = composition-da-a52e8d08d74bb225bb0d5cb64a7b9638

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa52e8d08d74bb225bb0d5cb64a7b9638"
* entry[=].resource = mpa52e8d08d74bb225bb0d5cb64a7b9638
                            
                    



Instance: mpa52e8d08d74bb225bb0d5cb64a7b9638
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Renagel 400 mg film-coated tablets"
Description: "Renagel 400 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/99/123/005  1 bottle of 360 film-coated tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Renagel 400 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: a52e8d08d74bb225bb0d5cb64a7b9638ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "renagel"

* status = #current
* mode = #working

* title = "List of all ePIs associated with renagel"

* subject = Reference(mp38d06c606097a82b9907752569c86e20)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#renagel "renagel"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-a52e8d08d74bb225bb0d5cb64a7b9638) // renagel en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-a52e8d08d74bb225bb0d5cb64a7b9638) // renagel da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-a52e8d08d74bb225bb0d5cb64a7b9638
InstanceOf: List

* insert a52e8d08d74bb225bb0d5cb64a7b9638ListRuleset
    